Tekmira files amended complaint against Alnylam.
M2 PHARMA-June 6, 2011-Tekmira files amended complaint against Alnylam(C)2011 M2 COMMUNICATIONS
6 June 2011 - Canadian RNAi therapeutics company Tekmira Pharmaceuticals Corp (TSX: TKM) said on Saturday it has filed an amended complaint against US-based Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) with the Business Litigation Session of the Massachusetts Superior Court.
Tekmira's amended complaint adds new claims alleging breach of contract, breach of the implied covenant of good faith and fair dealing, tortious interference with contractual relationships, and civil conspiracy. The amended complaint also adds AlCana Technologies Inc as a defendant and asserts claims alleging misappropriation of trade secrets, tortious interference with contractual relations, unjust enrichment, unfair and deceptive acts and trade practices, and civil conspiracy against AlCana. In the course of the litigation, Alnylam has asserted, among other claims that Tekmira is in breach of the licence and manufacturing agreements between the two companies.
As described in the amended complaint, Tekmira is seeking relief in the form of damages, including the royalties and profits Alnylam and AlCana would receive from the alleged improper use of Tekmira's technology and the termination of Alnylam's licence to Tekmira's technology.
((Comments on this story may be sent to firstname.lastname@example.org)).END.PUB430>PDJune 6, 2011>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 6, 2011|
|Previous Article:||Alnylam's ALN-VSP shows anti-tumour activity in Phase I trial in patients with solid tumours.|
|Next Article:||Study confirms MDV3100 clinical effects, tolerability in prostate cancer.|